Stockreport

ImmunityBio: Disconnect Between Clinical Progress And Stock Performance [Seeking Alpha]

ImmunityBio, Inc.  (IBRX) 
PDF ANKTIVA's Q4 revenue ramped to $38.3M, but high cash burn and speculative pipeline limit fair value to ~$3/share. Recent press releases, including NSCLC data and Saud [Read more]